Genmab Unveils a New Antibody Technology Platform: HexaBody

Genmab Unveils a New Antibody Technology Platform: HexaBody

Company Announcement

  *HexaBody platform is a novel technology platform to potently enhance
    antibody therapeutics
  *Multiple new business opportunities created
  *Additional details on technology platform to be provided today at Genmab's
    Post-ASH Seminar

COPENHAGEN, Denmark, Dec. 13, 2012 (GLOBE NEWSWIRE) -- Genmab A/S
(Copenhagen:GEN) announced today the addition of a new proprietary technology,
the HexaBody™ platform, to its suite of next generation antibody technologies.
The HexaBody platform is a novel technology that allows the creation of
differentiated antibody therapeutics by enhancing the natural target killing
abilities of antibodies in a fundamentally new way. The HexaBody platform will
be used to create novel differentiated antibody therapeutics, to improve the
efficacy of existing antibody products, and to potentially repurpose drug
candidates that were unsuccessful in previous clinical trials due to lack of

"We are very excited about the multiple new business opportunities the
HexaBody platform may create. This innovative technology will provide Genmab
and our potential partners with the possibility to improve upon existing
products and thereby extend their life cycles. We believe the HexaBody
platform provides cutting edge technology and the opportunity to create
fundamentally new products, robustly enhance existing products, and to
repurpose discontinued products," said Jan van de Winkel, Ph.D., Chief
Executive Officer at Genmab.

The HexaBody platform will be further described today at Genmab's Post-ASH
Seminar which can be viewed via webcast on our website at
2:00PM GMT / 3:00PM CET / 9:00AM EST. Webcast viewers may submit questions
during the Q&A portion of the live webcast via the webcast player or by
dialing +44 20 3140 0722 (international participants) or +1 718 705 7514 (US
participants) and asking for the Genmab call.

About the HexaBody platform

The HexaBody platform is Genmab's novel proprietary technology designed to
increase the potency of antibodies. Antibodies have a natural ability to
eliminate pathogens and tumor cells by various cytotoxic mechanisms. The
HexaBody platform strengthens the killing ability of antibodies while
retaining regular structure and specificity. The technology has the potential
to enhance antibody therapeutics for a broad range of applications in cancer
and infectious diseases.

About Genmab A/S

Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer.Founded in 1999, the company's first marketed
antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development.Genmab's validated and next generation
antibody technologies are expected to provide a steady stream of future
product candidates.Partnering of innovative product candidates and
technologies is a key focus of Genmab's strategy and the company has alliances
with top tier pharmaceutical and biotechnology companies.For more information


Rachel Curtis Gravesen, Senior Vice President, Investor Relations &

T: +45 33 44 77 20; M: +45 25 12 62 60; E:

This Company Announcement contains forward looking statements. The words
"believe", "expect", "anticipate", "intend" and "plan" and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to
the outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment
in relation to our business area and markets, our inability to attract and
retain suitably qualified personnel, the unenforceability or lack of
protection of our patents and proprietary rights, our relationships with
affiliated entities, changes and developments in technology which may render
our products obsolete, and other factors. For a further discussion of these
risks, please refer to the risk management sections in Genmab's most recent
financial reports, which are available on Genmab does not
undertake any obligation to update or revise forward looking statements in
this Company Announcement nor to confirm such statements in relation to actual
results, unless required by law.

Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD20®; DuoBody®, HexaBody™,
and UniBody® are all trademarks of Genmab A/S. Arzerra® is a trademark of

Company Announcement no. 40

CVR no. 2102 3884

Genmab A/S

Bredgade 34E

1260 Copenhagen K



40 HexaBody_uk_171212.pdf
Press spacebar to pause and continue. Press esc to stop.